재택 주입 요법 시장 규모, 점유율, 성장 및 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of home infusion therapy Market

The global home infusion therapy market is witnessing significant expansion, driven by the rising demand for cost-effective and patient-centric healthcare solutions. The market was valued at USD 42.44 billion in 2025 and is projected to grow to USD 45.67 billion in 2026, reaching USD 128.91 billion by 2034, exhibiting a strong CAGR of 13.85% during the forecast period. North America dominated the market with a 41.20% share in 2025, supported by advanced healthcare infrastructure and favorable reimbursement policies.

Home infusion therapy refers to the administration of medications such as biologics and intravenous drugs in a patient's home setting. This approach reduces hospital visits, lowers treatment costs, and enhances patient comfort. Increasing awareness of home-based healthcare, along with technological advancements in infusion devices, is accelerating global adoption.

Market Trends

A major trend shaping the market is the shift toward home-based medical care. Patients and healthcare providers are increasingly preferring home treatment due to convenience, reduced hospital stays, and lower risk of hospital-acquired infections. The integration of telehealth, wearable monitoring devices, and portable infusion systems has further improved the safety and efficiency of home infusion therapies.

Additionally, the COVID-19 pandemic accelerated this transition, as hospitals were overburdened and patients sought safer alternatives. The trend continues post-pandemic, with healthcare systems emphasizing decentralized care models.

Market Growth Drivers

One of the primary growth drivers is the rising prevalence of chronic diseases such as cancer, diabetes, and immune disorders. These conditions often require long-term infusion therapies, making home-based solutions highly attractive. The increasing geriatric population, which prefers receiving treatment at home, further supports market growth.

Another key factor is the growing demand for cost-effective healthcare. Home infusion therapy significantly reduces hospitalization expenses and associated costs. Studies indicate that home-based infusion treatments can be substantially cheaper than hospital-based care, encouraging wider adoption among patients and healthcare providers.

Moreover, increasing concerns about hospital-acquired infections are pushing patients toward home treatment options, especially those with compromised immune systems.

Market Restraints

Despite strong growth, the market faces certain challenges. The lack of reimbursement policies in developing regions remains a major barrier. High out-of-pocket healthcare expenses and limited insurance coverage restrict patient access to home infusion services.

Additionally, shortage of skilled healthcare professionals and limited infrastructure in emerging markets can hinder the widespread adoption of home infusion therapy.

Market Segmentation Analysis

By product type, the market is segmented into drugs, devices, and services. The drugs segment dominated the market with a 77.54% share in 2026, driven by increasing approvals of injectable therapies and a strong pipeline of biologics.

By indication, the market includes anti-infective therapies, chemotherapy, enteral nutrition, and others. The anti-infective segment led the market with a 25.52% share in 2026, owing to its widespread use and cost-effectiveness. Meanwhile, the chemotherapy segment is expected to witness the fastest growth due to rising cancer prevalence.

Regional Insights

North America remains the leading region, with a market size of USD 17.49 billion in 2025, growing to USD 18.69 billion in 2026. The region benefits from a strong network of home healthcare providers and supportive reimbursement frameworks.

Europe accounted for USD 13.69 billion in 2025 and is expected to grow steadily due to increasing government initiatives promoting home healthcare.

Asia Pacific, valued at USD 8.07 billion in 2025, is projected to witness the fastest growth due to rising healthcare awareness, increasing chronic disease burden, and expanding healthcare infrastructure in countries such as China and India.

Competitive Landscape

The market is moderately consolidated, with key players such as Option Care Health, Optum, CVS Health, and Baxter International focusing on expanding service offerings and technological innovations. Strategic collaborations, acquisitions, and partnerships are commonly adopted to strengthen market presence and improve patient access to home infusion services.

Conclusion

The home infusion therapy market is poised for robust growth, driven by the increasing need for cost-effective, patient-friendly healthcare solutions. With market value expected to rise from USD 42.44 billion in 2025 to USD 128.91 billion by 2034, the industry reflects strong long-term potential. While challenges such as reimbursement limitations and infrastructure gaps persist, advancements in technology, supportive government initiatives, and growing patient preference for home-based care will continue to drive market expansion.

Segmentation By Product

• Devices
• Drugs
• Services

By Indication

• Anti-Infective
• Chemotherapy
• Hydration Therapy
• Enteral Nutrition
• Total Parenteral Nutrition
• Immunoglobulin Therapy
• Others

By Geography

• North America (By Product, By Indication, and By Country)
  • U.S. (By Indication)
  • Canada (By Indication)
• Europe (By Product, By Indication, and By Country/Sub-region)
  • U.K. (By Indication)
  • Germany (By Indication)
  • France (By Indication)
  • Italy (By Indication)
  • Spain (By Indication)
  • Scandinavia (By Indication)
  • Rest of Europe (By Indication)
• Asia Pacific (By Product, By Indication, and By Country/Sub-region)
  • Japan (By Indication)
  • India (By Indication)
  • China (By Indication)
  • Australia (By Indication)
  • Rest of Asia Pacific (By Indication)
• Rest of the World (By Product and By Indication)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Chronic Diseases, Key Countries/Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Development such as Mergers, Acquisition, and Partnerships
• 4.4. Regulatory & Reimbursements Scenario, By Countries/Regions
• 4.5. Covid-19 Impact on the Market

5. Global Home Infusion Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Devices
  • 5.1.2. Drugs
  • 5.1.3. Services
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Anti-Infective
  • 5.2.2. Chemotherapy
  • 5.2.3. Hydration Therapy
  • 5.2.4. Enternal Nutrition
  • 5.2.5. Total Parenteral Nutrition
  • 5.2.6. Immunoglobulin Therapy
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of the World

6. North America Home Infusion Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Devices
  • 6.1.2. Drugs
  • 6.1.3. Services
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Anti-Infective
  • 6.2.2. Chemotherapy
  • 6.2.3. Hydration Therapy
  • 6.2.4. Enternal Nutrition
  • 6.2.5. Total Parenteral Nutrition
  • 6.2.6. Immunoglobulin Therapy
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
    • 6.3.1.1. By Indication
  • 6.3.2. Canada
    • 6.3.2.1. By Indication

7. Europe Home Infusion Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Devices
  • 7.1.2. Drugs
  • 7.1.3. Services
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Anti-Infective
  • 7.2.2. Chemotherapy
  • 7.2.3. Hydration Therapy
  • 7.2.4. Enternal Nutrition
  • 7.2.5. Total Parenteral Nutrition
  • 7.2.6. Immunoglobulin Therapy
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. U.K.
    • 7.3.1.1. By Indication
  • 7.3.2. Germany
    • 7.3.2.1. By Indication
  • 7.3.3. France
    • 7.3.3.1. By Indication
  • 7.3.4. Spain
    • 7.3.4.1. By Indication
  • 7.3.5. Italy
    • 7.3.5.1. By Indication
  • 7.3.6. Scandinavia
    • 7.3.6.1. By Indication
  • 7.3.7. Rest of Europe
    • 7.3.7.1. By Indication

8. Asia Pacific Home Infusion Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Devices
  • 8.1.2. Drugs
  • 8.1.3. Services
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Anti-Infective
  • 8.2.2. Chemotherapy
  • 8.2.3. Hydration Therapy
  • 8.2.4. Enternal Nutrition
  • 8.2.5. Total Parenteral Nutrition
  • 8.2.6. Immunoglobulin Therapy
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
    • 8.3.1.1. By Indication
  • 8.3.2. China
    • 8.3.2.1. By Indication
  • 8.3.3. India
    • 8.3.3.1. By Indication
  • 8.3.4. Australia
    • 8.3.4.1. By Indication
  • 8.3.5. Rest of Asia Pacific
    • 8.3.5.1. By Indication

9. Rest of the World Home Infusion Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Devices
  • 9.1.2. Drugs
  • 9.1.3. Services
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Anti-Infective
  • 9.2.2. Chemotherapy
  • 9.2.3. Hydration Therapy
  • 9.2.4. Enternal Nutrition
  • 9.2.5. Total Parenteral Nutrition
  • 9.2.6. Immunoglobulin Therapy
  • 9.2.7. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Option Care Health Inc.Overview
    • 10.2.1.1. Products & Services
    • 10.2.1.2. SWOT Analysis
    • 10.2.1.3. Recent Developments
    • 10.2.1.4. Strategies
    • 10.2.1.5. Financials (Based on Availability)
  • 10.2.2. Optum, Inc.
    • 10.2.2.1. Products & Services
    • 10.2.2.2. SWOT Analysis
    • 10.2.2.3. Recent Developments
    • 10.2.2.4. Strategies
    • 10.2.2.5. Financials (Based on Availability)
  • 10.2.3. CareCentrix, Inc.
    • 10.2.3.1. Products & Services
    • 10.2.3.2. SWOT Analysis
    • 10.2.3.3. Recent Developments
    • 10.2.3.4. Strategies
    • 10.2.3.5. Financials (Based on Availability)
  • 10.2.4. Lincare Holdings Inc.
    • 10.2.4.1. Products & Services
    • 10.2.4.2. SWOT Analysis
    • 10.2.4.3. Recent Developments
    • 10.2.4.4. Strategies
    • 10.2.4.5. Financials (Based on Availability)
  • 10.2.5. BriovaRx Infusion Services
    • 10.2.5.1. Products & Services
    • 10.2.5.2. SWOT Analysis
    • 10.2.5.3. Recent Developments
    • 10.2.5.4. Strategies
    • 10.2.5.5. Financials (Based on Availability)
  • 10.2.6. Promptcare
    • 10.2.6.1. Products & Services
    • 10.2.6.2. SWOT Analysis
    • 10.2.6.3. Recent Developments
    • 10.2.6.4. Strategies
    • 10.2.6.5. Financials (Based on Availability)
  • 10.2.7. Baxter
    • 10.2.7.1. Products & Services
    • 10.2.7.2. SWOT Analysis
    • 10.2.7.3. Recent Developments
    • 10.2.7.4. Strategies
    • 10.2.7.5. Financials (Based on Availability)
  • 10.2.8. B. Braun Melsungen AG
    • 10.2.8.1. Products & Services
    • 10.2.8.2. SWOT Analysis
    • 10.2.8.3. Recent Developments
    • 10.2.8.4. Strategies
    • 10.2.8.5. Financials (Based on Availability)
  • 10.2.9. Infusystem
    • 10.2.9.1. Products & Services
    • 10.2.9.2. SWOT Analysis
    • 10.2.9.3. Recent Developments
    • 10.2.9.4. Strategies
    • 10.2.9.5. Financials (Based on Availability)
  • 10.2.10. Moog Inc.
    • 10.2.10.1. Products & Services
    • 10.2.10.2. SWOT Analysis
    • 10.2.10.3. Recent Developments
    • 10.2.10.4. Strategies
    • 10.2.10.5. Financials (Based on Availability)